Asakawa et al. [13] evaluated the effect of thiazolidinediones in-vitro on cultured rat cardiac myocytes and in-vivo using mice (exposed to angiotensine II or pressure overload to induce hypertrophic remodeling) and observed that thiazolidinedione therapy inhibit cardiac hypertrophy. This evidence concerns the gene AGT and cardiac hypertrophy.